INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on reprogramming the patient's innate immune system to treat cancer Alzheimer's disease, and non-alcoholic steatohepatitis. The company intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma and patients with high-risk myelodysplastic syndrome; INB03 that treats patients with advanced cancers with elevated biomarkers of inflammation in their blood; XPro1595 for the treatment of Alzheimer's disease; LivNate to treat patients with non-alcoholic steatohepatitis; and Quellor for cytokine release syndrome and complications of COVID-19. The company has license agreements with Xencor, Inc.; Immune Ventures, LLC; University of Pittsburg; and University College London. INmune Bio, Inc. was incorporated in 2015 and is headquartered in La Jolla, California.